A parallel drug innovation system operating outside traditional pharmaceutical companies is delivering treatments at dramatically reduced costs, according to research from King's College London. Hospitals and universities are conducting late-stage clinical trials using generic drugs, finding new applications for existing medications like using cancer drugs to treat blindness or anti-inflammatory compounds for Covid.

These institutions achieve cost savings of over 90% compared to conventional pharmaceutical research. The study, published in the Cambridge Law Journal, identifies three main barriers to drug innovation—expertise, risk, and capital—that prove substantially lower when repurposing already-approved medications. Since the drugs are well-studied and manufactured, researchers can focus on specific applications within their existing expertise.

Pharmaceutical companies typically pursue 32 new drug uses annually during early development phases. However, once generic versions enter the market and competition intensifies, commercial interest wanes. This creates an opening for academic institutions whose motivations differ from patent-based incentives.

Clinicians and scientists in the repurposing system are driven by patient outcomes and academic advancement rather than profit maximization. They face reduced financial risk since no organization's viability depends on individual drug authorizations, allowing resources to flow toward treatments that might otherwise be abandoned.

The research reveals how academic-led drug repurposing creates a sustainable alternative to expensive pharmaceutical development, potentially expanding access to affordable treatments for underserved conditions.